Hormonal
GLP-1 receptor agonists (specifically liraglutide and semaglutide) reduce cardiovascular risk and may induce atherosclerotic plaque regression in patients with diabetes-associated atherosclerosis.
If you have diabetes and heart disease risk, ask your doctor about GLP-1 agonists like liraglutide or semaglutide. They don't just lower blood sugar; they protect your heart and may shrink arterial plaques. These are injectable drugs, but they offer significant cardiovascular benefits that oral medications may not.
Liraglutide and semaglutide have specifically been shown to decrease cardiovascular risk. Liraglutide has displayed a myriad of antiatherosclerotic properties, with the potential to induce plaque regression.
Why this rating
Cites major clinical trials (LEADER, SUSTAIN-6, SELECT) showing MACE reduction.
Source
The role of nanosystems in the delivery of glucose-lowering drugs for the preemption and treatment of diabetes-associated atherosclerosis
Luke Conroy et al. · American Journal of Physiology-Cell Physiology · 2024
DOI 10.1152/ajpcell.00695.2023
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →